Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MLH1 negative |
Therapy | Nivolumab |
Indication/Tumor Type | endometrial adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MLH1 negative | endometrial adenocarcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a Phase II trial (NCI-MATCH), Opdivo (nivolumab) treatment demonstrated preliminary efficacy in advanced solid tumor patients (excluding colorectal cancer) with deficient mismatch repair (defined by the loss of MLH1 or MSH2 expression by IHC), resulting in an objective response rate of 36% (15/42, 3 complete and 12 partial responses), including 2 complete responses and 2 partial responses in patients with endometrioid endometrial adenocarcinoma (n=13) (PMID: 31765263; NCT02465060). | 31765263 |
PubMed Id | Reference Title | Details |
---|---|---|
(31765263) | Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. | Full reference... |